Kayne Anderson Rudnick Investment Management LLC Invests $84.93 Million in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,087,620 shares of the company's stock, valued at approximately $84,932,000. Kayne Anderson Rudnick Investment Management LLC owned approximately 2.20% of Prestige Consumer Healthcare as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its position in shares of Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock valued at $19,630,000 after buying an additional 8,533 shares during the last quarter. Avior Wealth Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 1,570.7% during the fourth quarter. Avior Wealth Management LLC now owns 8,554 shares of the company's stock worth $668,000 after purchasing an additional 8,042 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 5.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock valued at $49,667,000 after purchasing an additional 33,844 shares during the last quarter. Norges Bank purchased a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $40,009,000. Finally, Barclays PLC boosted its position in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after purchasing an additional 71,730 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Oppenheimer boosted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research note on Thursday, February 13th. DA Davidson raised their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Canaccord Genuity Group lifted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Tuesday, April 8th. Finally, Royal Bank of Canada boosted their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research report on Friday, March 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $93.33.

Insider Transactions at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded up $0.99 on Friday, reaching $80.52. 270,919 shares of the stock were exchanged, compared to its average volume of 287,291. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $3.99 billion, a PE ratio of 18.86, a PEG ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The business has a fifty day moving average price of $83.60 and a two-hundred day moving average price of $80.48.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.